Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment
Background: Trastuzumab deruxtecan (T-DXd) shows efficacy in HER2-positive and HER2-low metastatic breast cancer (MBC), but its safety in patients with hepatic impairment is unclear. Methods: We report three cases of MBC patients with significant liver dysfunction treated with dose-reduced T-DXd aft...
Saved in:
| Main Authors: | Laura Sun, Gaybrielle Moore, Annalise Labatut, Jane Meisel, Kevin Kalinsky, Kristina Byers |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621924000590 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of trastuzumab deruxtecan therapy
by: Nina Privšek, et al.
Published: (2024-12-01) -
Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
by: Emad Dawoud, et al.
Published: (2025-01-01) -
Case report: Near-complete response to neratinib-based treatment in HR-positive HER2-amplified metastatic breast cancer refractory to trastuzumab deruxtecan
by: Ünal Metin Tokat, et al.
Published: (2025-01-01) -
The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by: Anna-Maria Lazaratos, et al.
Published: (2024-12-01) -
Response to trastuzumab deruxtecan and delayed immune-related events in a patient with metastatic HER2-positive NSCLC: a case report and literature review
by: Lu Wang, et al.
Published: (2025-01-01)